BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
Monday, January 6, 2020 1 min read
Key Takeaway: BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma
Full Press Release Details
BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation For Infigratinib In Adults With First-line Advanced Or Metastatic Cholangiocarcinoma And Orphan Drug Designation For Infigratinib For Treatment Of Cholangiocarcinoma.